[Anthropic CEO Predicts Conquering Cancer, Alzheimer's, and Even Doubling Human Lifespan Within a Decade: A Father Who Suffered from Testicular Cancer Didn't Receive Life-Saving Drugs] Beating AI News: Anthropic CEO Dario Amodei made a bold prediction during the company's IPO roadshow: cancer, Alzheimer's, heart disease, and mental illness may become history within 10 years. He believes that if the risks of AI can be properly controlled, humanity can usher in a "miracle era" of solving millennia-old problems. Back in 2024, Amodei proposed the concept of a "compressed 21st century" in his paper "Machines of Loving Grace": using AI with capabilities surpassing those of top scientists to achieve medical advancements that would normally take 50 to 100 years to accomplish, concentrated within 5 to 10 years. He even envisioned AI potentially reducing cancer incidence and mortality rates by over 95%, preventing Alzheimer's disease, and extending average human lifespan from approximately 75 to 150 years. Amodei has firsthand experience with disease and medical progress. He himself suffered from early-stage testicular cancer and successfully underwent treatment, while his father died of hepatitis C. Several years after his father's death, a new generation of antiviral drugs emerged, achieving a cure rate of approximately 95%. In September of this year, he revisited this experience, stating that he deeply understands what a few years' earlier medical breakthroughs mean for patients. Anthropic has begun personally participating in new drug development. In October, the company disclosed collaborations with six biopharmaceutical institutions, including Bristol-Myers Squibb, and acquired Mithril Medicine, a drug development company with only one full-time employee. Mithril's founder, using Claude to manage experiments, analyze data, and coordinate 11 external laboratories, advanced a potential treatment for a rare form of muscular dystrophy to animal trials in less than 18 months. Some of the treated mice showed approximately twice the grip strength and muscle strength of the untreated group, and their survival rate also improved. Anthropic anticipates that if subsequent experiments proceed smoothly, this drug could enter human clinical trials as early as the end of 2028. However, while AI can accelerate drug design and analyze experimental data, it cannot directly shorten the time required for the human body to produce therapeutic effects or experience long-term side effects. Especially for chronic diseases such as Alzheimer's, researchers may need to follow patients for years to confirm whether a new drug is truly effective. Amodei has previously acknowledged that clinical trials and regulatory approvals are major obstacles to accelerating medical progress. In an article published in June of this year, he pointed out that new drugs typically take about 7 to 8 years to obtain regulatory approval in the United States and Europe. He advocates using better AI simulations, toxicity predictions, and biomarkers to shorten the development cycle while retaining necessary safety verification. At the end of the IPO roadshow, Amodei also emphasized that only companies that can control AI risks and gain social trust are qualified to continuously develop and apply this technology. He linked his vision of curing major diseases with Anthropic's long-standing emphasis on AI safety. [Original Link]